Dr Reddy's Laboratories Limited
[WKN: 659157 | ISIN: US2561352038]
Aktienkurse
75,000$ -2,32%
Echtzeit-Aktienkurs Dr Reddy's Laboratories Limited
Bid: Ask:

Echtzeit-Chart der Dr Reddy's Laboratories Limited Aktie

Dr Reddy's Laboratories Limited Chart

Charttool öffnen

Börsenkurse Dr Reddy's Laboratories Limited

gettex - - - - 69,000€ -2,82%
Börse Stuttgart - - - - 68,500€ -2,84%
Echtzeit Euro - - - - 69,000€ -0,72%
Echtzeit USD - - - - 74,721$ -2,68%
Börse Frankfurt - - - - 69,000€ -3,50%
Lang & Schwarz - - - - 69,000€ -2,82%
New York - - - - 75,000$ -2,32%

Fundamentaldaten der Dr Reddy's Laboratories Limited Aktie

Income Statement: 10-Year-Summary

Datum Umsatz EBIT Gewinn EPS Dividende KGV KUV
2023 [USD] 3,06 Mrd. 746,55 Mio. 560,77 Mio. 3,38 0,55% 22,21 4,08
2022 [USD] 2,88 Mrd. 424,04 Mio. 316,31 Mio. 1,91 0,42% 39,33 4,33
2021 [USD] 2,56 Mrd. 349,34 Mio. 232,21 Mio. 1,40 0,37% 53,57 4,86
2020 [USD] 2,46 Mrd. 246,40 Mio. 274,98 Mio. 1,66 0,37% 45,21 5,05
2019 [USD] 2,20 Mrd. 314,61 Mio. 268,72 Mio. 1,62 0,35% 46,30 5,65
2018 [USD] 2,20 Mrd. 217,12 Mio. 152,11 Mio. 0,92 0,36% 81,79 5,65
2017 [USD] 2,10 Mrd. 213,31 Mio. 179,53 Mio. 1,08 0,39% 69,64 5,92
2016 [USD] 2,36 Mrd. 411,04 Mio. 305,68 Mio. 1,79 0,37% 41,85 5,41
2015 [USD] 2,42 Mrd. 457,42 Mio. 362,74 Mio. 2,13 0,39% 35,21 5,27
2014 [USD] 2,19 Mrd. 437,37 Mio. 356,01 Mio. 2,09 0,36% 35,82 5,83
Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet.

Weitere Informationen

Profil der Dr Reddy's Laboratories Limited Aktie

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Redd